Hypoxia-inducible
factor (HIF) inhibitor inhibits the HIF mediated hypoxic responses. HIF is a transcription
factor that activate when there is a decrease in the availability of oxygen in
the cellular environment. Hypoxia promotes the formation of blood vessels and
this homeostatic system is required in formation of vascular system in the
embryo.
Access
More About This Research at:
In
conditions like wounds, hypoxia mediate the migration of keratinocytes and
restores the epithelium. According to the researchers, the HIF plays a vital role
in the development of human body, as they are required by the body to adapt in
low oxygen concentration and maintain the metabolism. The therapeutic candidate
which acts as an HIF inhibitor has been found to improve the symptoms in
anemia, inflammatory disorders and cancer.
Request
to Get the Sample Pages at:
In addition,
HIF inhibitor have also been found to increase the erythropoietin expression
and enhance hippocampal memory. In addition, HIF is also essential for
immunological responses and is a key physiological regulator of homeostasis,
vascularization, and anaerobic metabolism.
Company like
FibroGen Inc. is developing roxadustat as a HIF prolyl hydroxylase inhibitor
for the treatment of anemia in chronic kidney disease (CKD) and myelodysplastic
syndrome (MDS).
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
